Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,720,900 papers from all fields of science
Search
Sign In
Create Free Account
CDX-110
Known as:
CDX 110
, CDX110
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
rindopepimut
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.
A. Heimberger
,
G. Archer
,
+8 authors
J. Sampson
Journal of Clinical Oncology
2016
Corpus ID: 7062514
2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise…
Expand
2016
2016
Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM.
J. Sampson
,
G. Archer
,
+7 authors
D. Mitchell
Journal of Clinical Oncology
2016
Corpus ID: 25330138
2034 Background: TRegs are increased in patients with GBM and constitutively express the high affinity interleukin-2 receptor (IL…
Expand
2014
2014
IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA
D. Reardon
,
J. Schuster
,
+13 authors
J. Sampson
2014
Corpus ID: 76584854
BACKGROUND: EGFRvIII, a constitutively active tumorigenic EGFR deletion mutation, is linked to poor long-term survival. The…
Expand
2013
2013
Patient selection for anti-EGFViii therapies in glioblastoma multiforme (GBM): Use of circulating tumor DNA.
E. Bahassi
,
M. Salkeni
,
C. McPherson
,
R. Warnick
,
O. Rixe
2013
Corpus ID: 199618202
e13023 Background: Several strategies have been recently developed to target EGFRvIII in Glioblastoma Multiforme (GBM), including…
Expand
2012
2012
REACT: A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB).
D. Reardon
,
J. Vredenburgh
,
+7 authors
J. Sampson
2012
Corpus ID: 79283012
TPS2103 Background: EGFRvIII is a constitutively active tumorigenic deletion mutation of EGFR. It is expressed in ~30% of primary…
Expand
2010
2010
Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).
R. Lai
,
L. Recht
,
+7 authors
J. Sampson
2010
Corpus ID: 74302009
2014 Background: EGFRvIII is a constitutively activated mutation of EGFR, not expressed in normal tissues but expressed in GBM…
Expand
2010
2010
Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
C. D. Del Vecchio
,
A. Wong
Current opinion in molecular therapeutics (Print)
2010
Corpus ID: 25566652
Celldex Therapeutics is developing rindopepimut (CDX-110), a 14-mer injectable peptide vaccine for the potential treatment of…
Expand
2008
2008
Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM
J. Sampson
,
G. Archer
,
+7 authors
A. Heimberger
2008
Corpus ID: 88357438
2011 Background: Conventional therapies for GBM fail to target tumor cells exclusively. Immunologic targeting of tumor- specific…
Expand
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 26153196
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 9963020
Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE